Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated diseases, has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary. Pangali, who previously served as Senior Vice President, Legal at Alumis, succeeds Sara Klein following her retirement.
In her new role, Pangali will oversee all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory. She brings significant experience from her previous positions at ACELYRIN, Snapdocs, and Principia Biopharma, where she held senior legal roles. Her background includes leading legal affairs through significant corporate events, including IPOs and mergers.
Alumis (Nasdaq: ALMS), un'azienda biofarmaceutica in fase avanzata focalizzata sulle malattie mediate dal sistema immunitario, ha promosso Sanam Pangali a Chief Legal Officer e Segretario Aziendale. Pangali, che in precedenza ricopriva il ruolo di Senior Vice President, Legal presso Alumis, succede a Sara Klein in seguito al suo pensionamento.
Nel suo nuovo incarico, Pangali supervisionerà tutte le funzioni legali e di conformità, inclusi la governance aziendale, la proprietà intellettuale e la consulenza strategica. Porta con sé una significativa esperienza maturata in precedenti ruoli presso ACELYRIN, Snapdocs e Principia Biopharma, dove ha ricoperto posizioni legali senior. Il suo background comprende la gestione di questioni legali durante importanti eventi aziendali, come IPO e fusioni.
Alumis (Nasdaq: ALMS), una empresa biofarmacéutica en etapa avanzada enfocada en enfermedades mediadas por el sistema inmunológico, ha promovido a Sanam Pangali a Chief Legal Officer y Secretaria Corporativa. Pangali, que anteriormente se desempeñaba como Vicepresidenta Senior Legal en Alumis, reemplaza a Sara Klein tras su jubilación.
En su nuevo rol, Pangali supervisará todas las funciones legales y de cumplimiento, incluyendo gobierno corporativo, propiedad intelectual y asesoría estratégica. Aporta una amplia experiencia de sus posiciones anteriores en ACELYRIN, Snapdocs y Principia Biopharma, donde ocupó cargos legales senior. Su trayectoria incluye liderar asuntos legales durante eventos corporativos significativos, como ofertas públicas iniciales y fusiones.
Alumis (Nasdaq: ALMS)는 면역 매개 질환에 중점을 둔 후기 단계 바이오제약 회사로, Sanam Pangali를 최고법률책임자 및 기업 비서로 승진시켰습니다. Pangali는 이전에 Alumis에서 법률 담당 수석 부사장으로 근무했으며, 은퇴한 Sara Klein의 후임입니다.
새로운 역할에서 Pangali는 기업 거버넌스, 지적 재산권 및 전략 자문을 포함한 모든 법률 및 준법 기능을 총괄할 예정입니다. 그녀는 ACELYRIN, Snapdocs, Principia Biopharma에서 고위 법률 직책을 역임하며 쌓은 풍부한 경험을 보유하고 있습니다. 그녀의 경력에는 IPO 및 합병과 같은 주요 기업 행사에서 법률 업무를 이끈 경험이 포함됩니다.
Alumis (Nasdaq : ALMS), une société biopharmaceutique en phase avancée spécialisée dans les maladies à médiation immunitaire, a promu Sanam Pangali au poste de Chief Legal Officer et Secrétaire Général. Pangali, qui occupait précédemment le poste de Senior Vice President, Legal chez Alumis, succède à Sara Klein à la suite de son départ à la retraite.
Dans ses nouvelles fonctions, Pangali supervisera toutes les fonctions juridiques et de conformité, y compris la gouvernance d'entreprise, la propriété intellectuelle et le conseil stratégique. Elle apporte une expérience significative acquise lors de ses précédents postes chez ACELYRIN, Snapdocs et Principia Biopharma, où elle a occupé des postes juridiques seniors. Son parcours inclut la gestion des affaires juridiques lors d'événements corporatifs majeurs tels que les introductions en bourse et les fusions.
Alumis (Nasdaq: ALMS), ein Biopharma-Unternehmen in der Spätphase, das sich auf immunvermittelte Erkrankungen spezialisiert hat, hat Sanam Pangali zum Chief Legal Officer und Unternehmenssekretär ernannt. Pangali, die zuvor als Senior Vice President, Legal bei Alumis tätig war, folgt auf Sara Klein nach deren Ruhestand.
In ihrer neuen Rolle wird Pangali alle rechtlichen und Compliance-Funktionen überwachen, einschließlich Corporate Governance, geistigem Eigentum und strategischer Beratung. Sie bringt umfangreiche Erfahrung aus früheren Positionen bei ACELYRIN, Snapdocs und Principia Biopharma mit, wo sie leitende juristische Funktionen innehatte. Ihr Hintergrund umfasst die Leitung rechtlicher Angelegenheiten bei bedeutenden Unternehmensereignissen wie Börsengängen und Fusionen.
- None.
- Loss of experienced CLO Sara Klein who led company through critical transitions
SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory on key decisions and transactions. Sanam succeeds Sara Klein, following her retirement from the company.
“We’re thrilled to elevate Sanam to the role of Chief Legal Officer,” said Martin Babler, President and Chief Executive Officer of Alumis. “She brings a sharp legal and business mind and has already proven to be an invaluable member of our senior executive team. Her counsel and leadership will be essential as we advance our late-stage pipeline and continue our mission to transform the lives of people living with immune-mediated diseases.”
“I also want to extend my deep gratitude to Sara, who has been with Alumis since the early days and played a pivotal role in our growth—including leading us through our IPO, our transition to a public company, and our merger with ACELYRIN. On behalf of the entire team, we thank Sara for her many contributions and wish her all the best in her retirement.”
Prior to joining Alumis in September 2024, Sanam served in various leadership roles at ACELYRIN, Inc., most recently as Chief Legal Officer and Head of People. She previously held senior legal roles at companies across the biopharmaceutical, technology, and renewable energy industries—including General Counsel at Snapdocs, Inc. and Associate General Counsel at Principia Biopharma through its acquisition by Sanofi. Sanam began her legal career in the Business & Finance practice group at Morrison & Foerster LLP, advising clients on financing, M&A, securities and corporate governance matters. She holds a J.D. from the University of Pennsylvania Carey Law School and a B.A. in Political Science from UC San Diego.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "expects," "may," "plans," "potential," "will" or similar expressions intended to identify forward-looking statements. All statements, other than statements of historical facts, including without limitation the potential for ESK-001 to treat moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and statements regarding Alumis’ future plans and prospects including development of its clinical pipeline, are forward-looking statements. Forward-looking statements in this press release are based on Alumis’ current expectations, estimates and projections as of the date of this release, and Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Readers are cautioned that actual results could differ materially and adversely from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, those related to Alumis’ ability to advance its clinical pipeline, obtain regulatory approval and ultimately commercialize its clinical candidates; the timing and results of preclinical and clinical trials; its ability to fund development activities; its ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC), including any future reports Alumis may file with the SEC from time to time.
Alumis Contact Information Teri Dahlman Red House Communications teri@redhousecomms.com
FAQ
Who is the new Chief Legal Officer of Alumis (ALMS)?
What is Sanam Pangali's background before joining Alumis (ALMS)?
What will be Sanam Pangali's responsibilities as CLO of Alumis (ALMS)?
When did Sanam Pangali join Alumis (ALMS)?
